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Despite more than two decades of research on preven-
tion and treatment of dementia and aging-related cognitive
decline, highly effective preventive and therapeutic strate-
gies remain elusive. Many features of dementia render it
especially challenging: supposedly distinct underlying pa-
thologies lead to similar clinical manifestations, develop-
ment of disease occurs insidiously over the course of
years or decades, and the causes of disease and determi-
nants of its severity are likely multifactorial. However,
progress in preventing and treating dementia also rests
on how dementia research is conducted: informative
research requires valid and rigorous analytic approaches,
and yet the research literature reflects little consensus on
“best practices.”
Several methodological challenges arise in studies of the
determinants of dementia risk and cognitive decline. Some
challenges, such as unmeasured confounding or missing
data, are common in many research areas; others, such as
outcome measurement error and lack of a “gold standard”
outcome assessment, are more pervasive or more severe in
dementia research [1–3]. Currently, researchers handle
these challenges differently, making it difficult to directly
compare studies and combine evidence. Although some
methodological differences across studies arise because
analytic methods are explicitly tailored to the study design
and realities of the data at hand, other differences arise
for less substantive reasons. Modifiable sources of
inconsistency include the absence of consensus and
definitive standards for best analytic approaches; different
disciplinary traditions in epidemiology, clinical research,
biostatistics, neuropsychology, psychiatry, geriatrics, and
neurology; and software and technical barriers.
The various analytic methods used in dementia research
often address subtly distinct scientific questions, depend
on different assumptions, and provide differing levels of sta-
tistical precision. Unfortunately, there is often insufficient
attention to whether a chosen method addresses the most
relevant scientific question and relies on plausible assump-
tions. Some common methods likely provide biased an-
swers—i.e., answers that diverge systematically from the
truth—to the most relevant scientific questions. Even if
several alternative approaches might be appropriate and
innovative or novel analyses used in individual studies
may be valuable, it can be advantageous to report results us-
ing a shared approach [4,5]. The “inconsistent application of
optimal methods” within and across studies makes it difficult
to qualitatively or quantitatively summarize results across
studies (meta-analyses). By contrast, a core set of shared
analytic approaches would enhance opportunities to
synthesize results and more conclusively address our
research questions. Applying a set of standardized
sensitivity analyses would help evaluate the plausible
magnitude of various sources of bias or violations of
assumptions. In randomized clinical trials (RCTs), forexample, there are strict rules regarding intention-to-treat
analyses, which are often complemented with additional ap-
proaches, such as per protocol analysis or modeling the
complier average causal effect to account for noncompli-
ance.
The CONsolidated Standards of Reporting Trials (CON-
SORT) [6] and Strengthening the Reporting of Observa-
tional studies in Epidemiology (STROBE) guidelines [7]
provide helpful indications of broad relevance in human sub-
jects research but are too broad to address several specific
methodological difficulties in dementia research. Topic-
specific guidelines building on STROBE have proven useful
in several domains, such as genetic association studies [8].
The MEthods in LOngitudinal research on DEMentia (ME-
LODEM) initiative was formed in 2012 to address these dif-
ficulties and achieve greater consistency in the process of
selecting and applying preferred analytic methods across
research on dementia risk and cognitive aging. The initial
MELODEM findings outline a set of methodological prob-
lems that should routinely be addressed in dementia
research, summarized in the guidelines in Fig. 1.We advance
this list as a working set of guidelines for transparent report-
ing of methods and results and therefore the best chance of
accelerating scientific progress in identifying determinants
as well as validating biomarkers for earlier diagnosis of Alz-
heimer’s disease (AD). The goals of MELODEM include
fostering methodological innovation to address these chal-
lenges and improving understanding of tools to address
each challenge. In this initial report from MELODEM, we
focus on outlining major categories of bias and why they
are especially relevant in dementia research. We briefly
discuss in the following, with more details in the online sup-
plement, five major challenges: (1) selection, i.e., handling
selection stemming from study participation, attrition, and
mortality; (2) measurement, i.e., dealing with the quality
of measurements of exposure and outcomes and how imper-
fect measurement quality affects analysis and interpretation
of results; (3) alternative timescale, i.e., specifying the time-
scale and the shape of trajectories in longitudinal models; (4)
time-varying exposures and confounding, i.e., accounting
for changes in explanatory variables; and (5) high-
dimensional data, i.e., analyzing complex and multidimen-
sional data such as neuroimaging, genomic information, or
database linkages.
For some topics in the checklist (Fig. 1), substantial
controversy remains regarding optimal analytic ap-
proaches, especially when considering both bias and vari-
ance of the methods. In many cases, although the
potential for bias is clear, it has not been established that
this bias is substantial in real data. The guidelines in
Fig. 1 are intended as a first step toward improved evalua-
tion and reporting of methodological challenges in demen-
tia research, to support a move toward field-wide consensus
on best practices, and identifying the highest priority areas
for methodological innovations.
Fig. 1. Guidelines for reporting methodological challenges and evaluating bias in cognitive decline and dementia research.
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research on dementia
2.1. Defining the scientific question of interest
Epidemiologic research in cognitive aging identifies cor-
relates of cognitive performance, cognitive decline, and de-
mentia. A critical first step in conducting effective research
is often taken for granted: clearly defining the scientific
question and distinguishing whether this question is causalor predictive [9]. Research on the etiology of dementia or
evaluating potential preventive or therapeutic interventions
seeks to address causal questions. Predictive studies, de-
signed for estimating prevalence or identifying high-risk in-
dividuals, are important for anticipating future trends in
public health burden of dementia and individual patient
outcomes. The analytic concerns of predictive studies
differ from those of studies intended to support causal infer-
ences.
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substantiated causal inferences, but providing evidence to
support causal inference is commonly the primary goal of
statistical analysis. Although conclusive inferences for
many treatments may ultimately depend on evidence from
RCTs, intervention trials are typically fielded only after
extensive observational research. This observational evi-
dence should be accumulated with the goal of illuminating
causal structures and guiding design of (eventual) trials.2.2. Selection into the analysis sample
Selection issues in dementia research arise from differen-
tial attrition of enrolled participants, differential survival of
enrolled participants, and differential enrollment, either due
to refusal to participate or differential survival up to the
moment of study initiation (Table 1 and Supplementary
Appendix 1). Each of these processes can bias effect esti-
mates. Spurious associations between the putative risk factor
and cognitive decline or dementia can occur when selection
processes are related to cognitive status and the exposure of
interest (or their determinants). The bias is not necessarily
toward the null (i.e., whichwould tend tomask an association)
and can sometimes reverse the direction of association
(i.e., making harmful exposures appear protective or protec-
tive exposures appear harmful) [10]. Impaired cognition
and dementia have broadly debilitating consequences, setting
the stage for selection bias in longitudinal studies of
dementia; risk of illness [11–15], death [16,17], and studyTable 1
Selection processes: problems and commonly adopted analytic approaches*
Differential attrition of enrolled participants Differential survival of enro
Approaches commonly applied to multiple selection problems
Ignore Ignore
Sensitivity analyses for magnitude of bias under
plausible set of selection processes
Sensitivity analyses for mag
plausible set of selection pr
Assess bounds based on best or worst case
assumptions
Assess bounds based on be
assumptions
Model determinants of selection to evaluate
whether ignoring selection is appropriate
Model determinants of sele
whether ignoring selection
Adjust for determinants of selection Adjust for determinants of
Weight on the inverse of the probability of
selection
Weight on the inverse of th
selection
Instrumental variable methods, if an instrument
for selection is available
Instrumental variable metho
for selection is available
Joint modeling of selection process (dropout,
death, enrollment) and outcome
Joint modeling of selection
death, enrollment) and outc
Approaches commonly applied only to specific selection problems
Multiple imputation and likelihood-based
estimation including covariates related to
missingness mechanism
Competing risks analysis (o
the outcome)
*For many of these approaches, there is currently limited empirical or theoretica
the effect of interest) in dementia research.attrition [18–20] are all heightened among persons with
impaired cognition. Selection bias is likely to result if the
risk factor under study is associated with attrition as well.
For example, chronic disease, adverse health behaviors,
socioeconomic status, and race are all associated with
substantial morbidity and mortality risks [3,21–25]. Various
approaches are adopted to address potential selection bias
(Table 1), but the performance of these approaches has rarely
been evaluated. Even the likelihood of substantial bias from
“ignoring the selection process,” which is arguably the most
common strategy in the applied literature, is rarely formally
quantified, although specific examples suggest it may be
reasonably large. In the Chicago Health and Aging Project,
accounting for selective attrition increased estimated associa-
tions between smoking and cognitive decline by 56%–86%
[26].MELODEMguidelines are intended to provide evidence
to evaluate whether selection is likely to introduce a substan-
tial bias.
Over the course of longitudinal follow-up, many older
participants may “drop out” or refuse continued study partic-
ipation. If drop-out is dependent on measured parameters
(a “missing at random” mechanism”), several analytical ap-
proaches can provide unbiased effect estimates; however, if
drop-out is dependent on unknown or unmeasured parame-
ters, there is no easy solution for bias correction (Table 1).
In this situation, sensitivity analyses can illuminate the
robustness of the findings [27].
Mortality is also a significant source of censoring in lon-
gitudinal studies. Many approaches considered appropriatelled participants Differential study enrollment or “muting”
Ignore
nitude of bias under
ocesses
Sensitivity analyses for magnitude of bias under
plausible set of selection processes




Model determinants of selection to evaluate
whether ignoring selection is appropriate
selection Adjust for determinants of selection
e probability of Weight on the inverse of the probability of
selection
ds, if an instrument Instrumental variable methods, if an instrument
for selection is available
process (dropout,
ome
Joint modeling of selection process (dropout,
death, enrollment) and outcome
nly when dementia is Principal stratification
l evidence comparing the performance (i.e., providing a precise estimate of
J. Weuve et al. / Alzheimer’s & Dementia 11 (2015) 1098-11091102for handling dropout-related attrition are more controver-
sial in the context of survival, and there is no current
consensus on preferred approaches [28]. Although cogni-
tive function is “missing” for individuals who drop out of
a study, it is more appropriately described as “undefined”
for people who die [29]. This conceptualization suggests
that people whose survival is determined by exposure
should be excluded from the population for whom we try
to estimate effects. For example, smoking may predict
lower dementia diagnosis rates by causing earlier mortality
from other causes [2]. Thus, the central challenge when ad-
dressing selective survival is to clearly define the question
of scientific interest [28,29]: what parameter are we trying
to estimate, for whom are we trying to estimate it, and
which analysis methods correspond with this estimand
(Table 1)?
In dementia cohort studies, truncation of follow-up by
death also introduces interval censoring, which occurs
because diagnosis of dementia can only be made at periodic
follow-up visits. Therefore, dementia status at death is un-
known for participants who were free of dementia at their
last visit before death. Interval censoring in the presence of
competing risk of death can induce an underestimation of de-
mentia incidence and alter estimated effects of exposures
[23,25]. For example, the protective effect of high education
on the risk of dementia was overestimated by 36% in men
when not accounting for interval censoring in the French
PAQUID cohort. This was likely because, while higher
educational attainment predicts elevated risk of dementia
diagnosis, it also predicts faster death after the diagnosis [25].Fig. 2. Hypothetical illustration of selection processes before and after study enr
factors synergistically affect mortality, with more than multiplicative effects on su
are very unlikely to be APOE 34 carriers. Analyses that did not control for APOE
effects of smoking.Bias may also arise from how participants are selected
into a study if enrollment is influenced by the exposure of
interest and the outcome (or their determinants). Similar
biases may occur whether differential enrollment occurs
because people with particular dementia risk factors system-
atically refuse study participation or because these people
are unlikely to survive to the age of enrollment. Consider a
hypothetical study of the effect of smoking on AD, enrolling
participants at age 70 (Fig. 2). If the effects of smoking and
APOE- 34 status on mortality are synergistic (i.e., more than
multiplicative), then the surviving 70-year-old smokers will
have a lower APOE- 34 prevalence than 70-year-old
nonsmokers. The study may conflate effects of APOE- 34
with the effects of smoking. Pre-enrollment selectivemortal-
ity is particularly likely in population-based studies of older
adults: persons exposed to detrimental risk factors may have
survived to the age of enrollment only by virtue of their un-
usually effective detoxification genotype or cognitive
acumen. Challenges arising from selective enrollment are
broadly recognized, although the potential for this selection
to compromise both generalizability and internal validity is
sometimes disregarded.
Each of these selection processes may partially “mute”
effect estimates. For example, the association between
smoking and AD progressively attenuates, or even be-
comes protective, in older samples [2]. Similar muting ef-
fects with increased participant age are apparent for
multiple other risk factors [2,22,30–33]. Selection may
also create spurious differences in effect estimates
between subgroups.ollment. At age 20, smoking and APOE status are unrelated, but these risk
rvival up to age 70 [72]. By the time of study initiation at age 70, smokers
34 would conflate APOE status and smoking and spuriously underestimate
J. Weuve et al. / Alzheimer’s & Dementia 11 (2015) 1098-1109 1103Table 1 summarizes these problems and commonly
adopted analytic approaches to addressing issues of selec-
tion. Evaluating the usefulness of each approach and
how each of these approaches perform in specific situa-
tions in dementia research is an important methodological
question.
Although issues of selective attrition and selective sur-
vival affect both observational research and RCTs, selective
enrollment does not compromise the internal validity of
RCTs (although may reduce generalizability) conferred
through randomization.2.3. Measurement validity and reliability
Measurement challenges in dementia research result
from the disjuncture between disease pathophysiology
and clinical and research measures, due to imperfect val-
idity and reliability (detailed in Supplementary Appendix
2). For example, performance on neuropsychological tests
does not necessarily precisely reflect biological func-
tioning and capacity of the brain. Similar measurement
challenges pertain to measures of the consequences,
severity, and progression of dementia, including func-
tional dependency, neuropsychiatric symptoms, and
behavioral patterns [34]. Distinguishing between neuro-
pathologic processes in the brain and cognitive symptom
trajectories is important to elucidate specific causal path-
ways to disease and possible interactive effects on closely
related outcomes.
Validity refers to whether a measurement instrument as-
sesses the phenomenon of interest. Gold standard measures
can be used to assess the validity of alternative measure-
ments, but there is often no clear gold standard in dementia
research. Measures valid for one group of people may not be
valid for another, leading to biased estimates of disparities
and risk factor effects [35,36]. For example, historical
inequalities in educational access for African-Americans
compared with white Americans have led to systematic dif-
ferences in literacy levels in older adults. These literacy dif-
ferences appear to contribute to racial disparities in dementia
risk [35,36].
Identifying valid dementia biomarkers is critical but
many efforts risk circular reasoning, in which we use clinical
diagnoses to validate biomarkers and those same biomarkers
to validate the clinical diagnoses [37]. Indeed, even the
phenotype of interest is often controversial, and it is likely
that many common disease definitions include diverse un-
derlying pathologies.
Reliability is the proportion of variability in a
measure explained by the construct of interest, as opposed
to the proportion attributable to measurement error
(random fluctuations in the measurement not reflecting
changes in the underlying construct) [38,39]. Nearly
all neuropsychological assessments have substantial
unreliability, which reduces statistical power and
introduce the potential for regression to the mean.Practice or retest effects arising from changes in famil-
iarity with the testing process, use of strategies, or recall
of test-specific content can also hamper detection of
cognitive decline [40] because practice effects can be
large enough to offset several years of cognitive decline
in elderly adults [41]. Cognitive declines stemming from
incipient dementia may thus be impossible to detect
because of practice-related improvements on test perfor-
mance [41]. Practice effects could lead to underestimation
of the rate of cognitive decline, incidence of dementia,
and, if the magnitude of practice effects differs by
background characteristics, to incorrect inferences about
determinants of cognitive decline [41,42]. Statistical
approaches for handling practice effects remain
controversial (Table 2) [43,44].
Another measurement challenge comes from the
assumption made by most common analytic methods
that a 1-point difference in a test score has the same sub-
stantive meaning at high and low ends of the scale. A
decline in Mini-Mental State Examination (MMSE) score
from 25 to 24, however, may not be equivalent to a
decline from 20 to 19. Ceilings and floors constitute
extreme examples of such unequal interval scaling. Ceil-
ings and floors attenuate effect estimates in cross-
sectional analyses but may either attenuate or inflate ef-
fect estimates in longitudinal analyses [1]. An extensive
simulation study showed that failing to account for un-
equal interval scaling of psychometric tests when studying
effects of a risk factor on cognitive slope can substantially
inflate type 1 errors (i.e., spurious associations) if the risk
factor also predicts baseline cognitive level [45].
2.4. Alternative timescales and specification of
longitudinal models
The specification of the timescale(s) and functions of
within-person change in longitudinal studies can dramat-
ically influence results and replicability. Because of the
close link between age and dementia, age constitutes a
natural and appropriate timescale for studying dementia
risk or related binary outcomes [46–48]. In studies of
cognitive ageing, this also applies when studying time-
invariant exposures (such as gender or genes). However,
research often addresses time-varying exposures that
are measured only once during the study (e.g., nutrition,
diabetes, treatment) and thus at different ages. In this sit-
uation, using the time since exposure measurement (usu-
ally enrollment) as the timescale may be more
appropriate. When focusing on specific phases of cogni-
tive aging such as the prodromal phase of dementia or
terminal decline, reverse time (e.g., years before diag-
nosis or death) may also be informative [44,49].
However, using reverse time inherently selects
participants who developed the outcome, which might
cause biases in estimated longitudinal changes. This is
an active area of methods development, with several
approaches used in the current literature (see section
Table 2
Measurement challenges: problems and commonly adopted analytic approaches*
Validity of measurement
Reliability/random
measurement error Practice or retest effects
Unequal-interval scaling (including
ceilings/floors on measures)
Approaches commonly applied to multiple measurement problems
Ignore Ignore Ignore Ignore
Multivariate latent variable methods
or measurement error models
Multivariate latent variable methods
or measurement error models
Approaches applied only to specific measurement problems
Compare to a gold standard/criterion
validity
Instrumental variable analyses Drop the first assessment or average
first two assessments
Drop observations at the ceiling/
floor or otherwise condition on the
baseline score
Compare to measures of
theoretically correlated variables
Use composite scores from multiple
neuropsychological assessments
(e.g., summed Z-scoresy)
Choose tests with limited retest
effects
Item response theory or factor




Functioning (DIF) and implement
statistical corrections or adjustment
for source of DIF
Randomize time of first assessment Rescale by Z-scoringy
Indicator for first assessment Transform the measure with a
monotonic transformation intended




Other models of practice (linear or
non-linear increases in practice
effects)
Categorize the outcome (impaired
vs. not impaired)
Mixed models identifying practice
effects based on time-varying
interview delays
Tobit regression models (for
ceilings/floors) or quantile
regressions
Joint estimation of a normalizing
transformation of the outcome and
the coefficients
*For many of these approaches, there is currently limited empirical or theoretical evidence comparing the performance (i.e., providing a precise estimate of
the effect of interest) in dementia research.
yZ-scoring rescales each individual’s raw score with respect to the distribution of scores for other individuals in the sample. From each individual’s raw score,
the Z-score is calculated by subtracting the sample mean (usually at baseline) and dividing by the sample standard deviation (also at baseline).
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cess presumed to be relevant should guide the choice of
metrics [50] (Table 3).
Most observational studies on cognition recruit partic-
ipants over a wide age range so that studying cognitive
change with age mixes two processes: within-person
change with age (usually of main interest) and between-
person age differences that are also influenced by birth
cohort. Ignoring age differences at baseline when studying
cognitive decline with age is appropriate only if individ-
uals “converge” onto the same age trajectory whatever
their birth cohort: i.e., if a person entering at 85 years is
expected to have the same cognitive level as a person
entering at 65 years and followed for 20 years. This
may be unrealistic [50,51]. For example, for women in
the Whitehall cohorts, between-person age effects
overestimated rate of cognitive decline compared withwithin-person effects because of large cohort differences
in educational levels [52]. The “convergence” issue can
be easily disentangled by distinguishing two timescales:
a longitudinal timescale (e.g., current age or time since
enrollment) for within-person change and a cross-
sectional timescale (e.g., age at enrollment) for
between-person age differences (Table 3).
Average year-to-year cognitive changes are not expected
to be the same at all ages; cognitive decline may accelerate
at older ages. In studies with short follow-ups, linear
approximations may be adequate [53] but with longer
follow-up, age-heterogeneous samples, or pathologic
events, linearity rarely holds. Approaches to account for
this heterogeneity include polynomial cognitive trajec-
tories [54]; biphasic trajectories with change points
[55,56] or nonparametric estimation of cognitive
trajectories [49].
Table 3
Defining the time scale for longitudinal analyses: problems and commonly adopted analytic approaches*
Divergence of within-person change and
between-person age differences
Analysis of terminal decline preceding death,
dementia, or other “milestone” events Nonlinear cognitive trajectories
Approaches commonly applied to multiple time scale problems
Ignore Ignore Ignore
Approaches applied only to specific time scale problems
Age as the time-scale with adjustment for age
at entry or time-from-entry as the time-scale
adjusting for age at entry
Analysis among the participants who had the
event
Polynomial trajectory (quadratic, cubic)
Use of age at assessment as the time scale,
without adjustment for age at entry.
Time to event as time scale in the group with
event versus time to last measure for the
healthy participants matched by or adjusted for
the age at the last measure among others
Trajectories with random, pre-specified, or
empirically selected change-points
Other time scale of interest adjusting for a
cross-sectional age (possibly other than age at
entry)
Joint model of the longitudinal outcome and
the time to the event of interest (death,
dementia or others)
Flexible parametric (splines, fractional
polynomials) or non-parametric trajectories
*For many of these approaches, there is currently limited empirical or theoretical evidence comparing the performance (i.e., providing a precise estimate of
the effect of interest) in dementia research.
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the problems of timescales.2.5. Time-varying exposure/time-varying confounding
Pathologic brain changes are evident at least two de-
cades before clinical dementia diagnosis. Effects of expo-
sure on cognitive outcomes may depend on when
exposure occurs, and the relevant timing likely differs for
exposures influencing pathogenesis, disease progression,
and/or maintenance of function. Research identifying
relevant etiologic periods is essential for guiding clinical
decisions and preventive interventions targeting known
risk factors. For example, elevated blood pressure in
midlife predicts higher dementia risk, whereas elevatedTable 4
Handling time-varying exposures and time-varying confounding: problems and co
Time-varying exposures
Approaches commonly applied to both time-varying exposures and time-varying c
Ignore
(e.g., consider variable at a single point in time)
Marginal structural models and inverse probability weighting
Structural nested models
Approaches commonly applied to either time-varying exposures or time-varying c
Time-to-event models, allowing exposure to update or lag
Summaries of time-varying exposure (e.g. average, duration, age at
initiation)
Compare estimates from several models using exposure status at a single
point in time or moving time windows; formally test alternative
lifecourse models.
*For many of these approaches, there is currently limited empirical or theoretica
the effect of interest) in dementia research.blood pressure late in life does not [33,57–59]. Although
the explanation for this difference is unclear,
recommendations on hypertension treatment for dementia
prevention must be tailored to a person’s age and existing
morbidities. A “critical window” hypothesis has been
suggested for hormone therapy effects on dementia, with
benefits from initiation in the perimenopausal period but
harms from later initiation [60]. A recent systematic review
identified only a handful of studies directly addressing this
question [61]. For evaluating etiologic periods, cohorts
with very long follow-up (e.g., PREVENT [62] or the
Framingham Heart Study [63]) are informative because
they provide measures of exposure at multiple ages.
Quantifying how an exposure’s effects on dementia evolve




(e.g., consider variable at a single point in time)
Marginal structural models and inverse probability weighting
Structural nested models
onfounding
Compare effect estimates with or without adjustment for time-varying
confounders
Longitudinal propensity score models
Instrumental variables models
l evidence comparing the performance (i.e., providing a precise estimate of
Table 5
Handling high dimensional data: challenges and commonly adopted analytic approaches
Multiple comparisons/false discovery
Summarizing multiple highly correlated
variables Regression with high dimensional data
Family wise error correction (e.g. Bonferroni) Theoretically motivated summaries or selected
indicators based on prior knowledge, e.g.,
candidate gene approaches
Preselection of the variables of interest for
adjustment
False discovery rate (e.g. BH correction) Combination of variables (e.g. principal
components analysis, partial least square)
Regularization methods (e.g. Lasso, ridge
regression, elastic net)
J. Weuve et al. / Alzheimer’s & Dementia 11 (2015) 1098-11091106methods of analyzing time-varying exposure data can yield
results that vary substantially in magnitude and, more
crucially, in interpretation (Table 4) [64]. Although risk
factor-dementia associations that differ by age at exposure
may reflect relevant etiologic windows, they could also
reflect reverse causation or measurement error that differs
across age-specific exposures. When cumulative effects of
long-term exposure, rather than variation in exposure or
point in time exposure effects, are hypothesized, repeated
measures of exposure can be combined (e.g., averaged)
to achieve more precise exposure estimates.
Just as exposures may vary over time, so too may
confounders. Adding to the challenge are differences across
studies in how and when exposures and potential con-
founders are measured. Similar to analyzing time-varying
exposure data, adequately adjusting for confounding when
exposures and confounders change over time requires
special care, especially when confounders also act as
potential mediators [65].
The Supplementary Appendix 4 provides further detail on
and examples of the problems of time-varying exposures and
confounders.2.6. High-dimensional data
The proliferation of data sources and emergence of high-
dimensional data could powerfully accelerate dementia
research but only if harnessed effectively [66]. Administra-
tive databases, omics data, brain imaging data (magnetic
resonance imaging and positron emission tomography),
biomarker panels assessing gene expression, and metabolic
pathways, among many others, present both new challenges
and opportunities (Supplementary Appendix 5).
New technologies will provide information on numerous
biomarkers, which may help us distinguish more specific
dementia phenotypes, but we need strong measurement tools
to better take advantage of these data.
Challenges in the statistical analyses of high-
dimensional data are numerous (Table 5), even when the
number of observations is much larger than typically avail-
able in research cohorts. Big data do not necessarily resolve
the familiar internal and external validity challenges in
epidemiologic studies and may in some situations exacer-
bate challenges with measurement validity and selection
bias. For example, dementia is known to be substantiallyunderrepresented in many US administrative databases,
due to underdiagnosis. Underdiagnosis rates may differ
by demographic or other background variables [67]. A pro-
vocative and unexpected finding was recently reported
from a UK administrative database (UK Clinical Practice
Research Datalink) with almost 2 million individuals
ages 40 years, accruing over 45,000 incident dementia
cases [68]: obese people carried a third lower risk of devel-
oping dementia than their normal weight peers. The huge
sample provided very precise effect estimates but also en-
tailed numerous tradeoffs that may have introduced biases,
such as limited confounder control based on variables re-
corded in the database and potential for misclassification
of the outcome [69].
Recent worldwide efforts to merge data from multiple
dementia cohorts are generating unique and promising
databases: the European Medical Information Framework-
AD, a partnership of academics, pharmaceutical com-
panies, and medical informatics specialists focuses on
the identification of preclinical biomarkers of AD.
Despite huge sample sizes, results will be useful only if
it is possible to derive harmonized measures of exposure,
biomarkers, and outcomes. Coordinating such efforts is a
major challenge [66]. The Integrated Analysis of Longitu-
dinal Studies of Aging collaboration focuses on data
harmonization and reproducibility of research from
international longitudinal studies focused on aging and
health-related change in cognition, health, and well-
being [70].
High-dimensional data analysis generates multiple statis-
tical comparisons/tests potentially addressed by various sta-
tistical corrections (family-wise error and false discovery).
A related issue is possible “overfitting” (i.e. when a statisti-
cal model describes random error or noise instead of the
underlying relationship). In this case, dimension reduction
techniques can be used either during or before supervised
analyses (e.g., Lasso or partial least-squares methods). The
challenges here are both to account for the high dimension-
ality in models (multiple testing and overfitting) and to
extract meaningful information from these data to better
understand dementia etiology.
New data sources may allow more powerful hypothesis-
driven research, i.e., evaluating prespecified social,
behavioral, or clinical determinants of dementia, and also
agnostic search conducted in the absence of clearly specified
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because of type 1 error problems, but this is an important
frontier for the field.
With the growing availability of biomarkers in large data
sets, there may be new opportunities to evaluate interactive
effects of risk factors and pathologic processes. For example,
researchers may be able to model whether genetic or behav-
ioral risk factors influence cognitive symptoms differently
depending on level of underlying neuropathology. Impor-
tantly, because many but not all risk factors will directly
influence neuropathology, this will entail careful mediation
models to decompose direct, indirect, and interactive path-
ways.
The Supplementary Appendix 5 provides further detail on
the problems of high-dimensional data.3. Conclusion
Clinical and epidemiologic research over the past two
decades has witnessed a remarkable movement toward
improved transparency, reproducibility, and methodolog-
ical rigor, as reflected in the CONSORT [6,71],
STROBE [7], and recently STARDdem [37] guidelines.
Although the STROBE recommendations apply to studies
of dementia, they provide quite general suggestions, with
little guidance on many important issues of special
salience in dementia and cognitive ageing research. The
MELODEM guidelines fill this gap. Embracing and
expanding on the foundation of STROBE and related
efforts could strengthen and accelerate dementia
research.
The MELODEM guidelines, highlighting a set of
common methodological challenges in longitudinal research
on dementia, complements STROBE and CONSORT guide-
lines but focuses on technical challenges specific to
dementia-related research. We hope researchers adopting
the MELODEM guidelines will routinely acknowledge
these challenges and justify analytic decisions. We antici-
pate that MELODEM will provide a platform for continued
discussion and innovation of methodological tools to
strengthen dementia research.
The guidelines indicate standards for reporting but do
not make specific recommendations for how to best
address analytic challenges. Ideally, consensus recom-
mendations for “common denominator” analyses will
emerge in coming years to facilitate meta-analyses and
integration of evidence. Findings from common denomi-
nator analyses could routinely be included in research ar-
ticles, alongside additional methodological approaches
based on research team innovations or particular strengths
of the data set.
Observational studies suggest major differences
in prevalence and incidence of dementia-related pheno-
types across population groups; these differences
represent opportunities to prevent dementia, if we can
identify the reasons for epidemiologic patterns. Suchresearch will only be effective if we can overcome the
methodological challenges discussed here. The chal-
lenges are not trivial, and these difficulties have
presented important barriers to progress in research on
the determinants of dementia incidence and progression.
The most powerful statistical solutions may require
capacity building, including new software and skills
development, before they will be broadly adopted.
Alongside major investments in strengthening measure-
ments via genotyping, neuroimaging, and biomarker
assessments, methodological advances hold promise to
accelerate progress toward successful prevention and
treatment of dementia. Indeed, without strong research
methods, the investments in high-quality measures will
be of little use.
Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jalz.2015.06.1885.RESEARCH IN CONTEXT
1. Systematic review: Clinical and population research
on dementia and related neurologic conditions,
including Alzheimer’s disease, faces several unique
methodological challenges. Progress to identify pre-
ventive and therapeutic strategies rests on valid and
rigorous analytic approaches, but the research litera-
ture reflects little consensus on “best practices.”
There is a great need for guidelines addressing spe-
cific issues to dementia/cognitive ageing research,
in line to those developed through the Enhancing
the QUAlity and Transparency Of health Research
(Equator) network.
2. Interpretation: Several methodological challenges
arise in studies of the determinants of dementia risk
and cognitive decline. Currently, researchers handle
these challenges differently, making it difficult to
directly compare studies and combine evidence.
Guidelines were generated through the international
initiative MELODEM (MEthods for LOngitudinal
studies in DEMentia) to outline a set of methodolog-
ical problems that should routinely be addressed in
dementia research.
3. Future directions: We hope researchers adopting the
MELODEM guidelines will routinely acknowledge
these challenges and justify analytic decisions. We
anticipate that MELODEM will provide a platform
for continued discussion and innovation of methodo-
logical tools to strengthen dementia research.
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